Literature DB >> 30283274

Rh-Matched Transfusion through Molecular Typing for β-Thalassemia Patients Is Required and Feasible in Chinese.

Chao-Peng Shao1, Cheng-Jiang Zhao2, Chang-Lin Wu1, Hua Xu3, Xue-Dong Wang4, Xiao-Ying Wu5, Ping Yi1, Xin-Tang Dang1.   

Abstract

BACKGROUND: Molecular typing for RHCE blood group alleles has been established in many countries for patients and blood donors. In the Chinese literature nearly 80% of transfused patients with alloimmunization have antibodies specific for antigens of the Rh blood group system. We investigated if it is feasible to match packed red blood cells (RBCs) for Chinese β-thalassemia patients by RHCE genotyping.
METHODS: In this study, 481 patients with β-thalassemia were enrolled. They were genotyped for RHCE alleles by a simple PCR method with sequence-specific primers (PCR-SSP). Among these patients, 203 continuously received RBCs of the identical Rh subgroups according to the genotyping results for at least 3 months. Subsequently, their phenotypes were tested through a micro-column gel card method. For validation purposes, 400 donors were serologically typed with the same technology, of which 164 were genotyped too. Finally, the C, c, E, and e frequencies and the feasibility of the simple genotyping method were analyzed.
RESULTS: All patients showed mixed-field agglutination in the Rh subgroup gel cards before the same Rh subgroups in blood donors were selected for blood transfusion. The results, however, lacked mixed-field agglutination in all 203 cases after transfusion with RBC concentrates selected for the patient's C, c, E, and e antigens for at least 3 months. The genotyping results of 164 donors were all consistent with the serological results. Whole coding regions of RHCE were sequenced in 7 individuals with weak c, E, or e antigens. In only one sample we observed a 1059G>A nucleotide mutation coding for a truncated RhCE polypeptide (GenBank KT957625), in the other 6 samples no sequence variant was found. Both patients and donors were predominantly CcEe and CCee, with a prevalence of 55.3% and 24.9% for patients or 49.3% and 31.3% for donors, respectively. It revealed that about 80% of Chinese could receive Rh-matched RBCs easily.
CONCLUSION: A simple RHCE genotyping technique is safe enough for Rh-matched transfusion of β-thalassemia patients in Chinese Han.

Entities:  

Keywords:  RHCE genotyping; Rh-matched transfusion; β-Thalassemia

Year:  2018        PMID: 30283274      PMCID: PMC6158581          DOI: 10.1159/000489471

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  26 in total

Review 1.  The role of molecular immunohematology in sickle cell disease.

Authors:  Stella T Chou; Connie M Westhoff
Journal:  Transfus Apher Sci       Date:  2011-01-28       Impact factor: 1.764

Review 2.  Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing.

Authors:  A Matteocci; L Pierelli
Journal:  Vox Sang       Date:  2013-10-09       Impact factor: 2.144

3.  Applying molecular immunohaematology to regularly transfused thalassaemic patients in Thailand.

Authors:  Pairaya Rujirojindakul; Willy A Flegel
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

4.  Blood group genotyping in multi-transfused patients.

Authors:  Sule Mine Bakanay; Aysenur Ozturk; Talia Ileri; Elif Ince; Suzan Yavasoglu; Nejat Akar; Zumrut Uysal; Onder Arslan
Journal:  Transfus Apher Sci       Date:  2013-02-21       Impact factor: 1.764

5.  RHD and RHCE genotyping by next-generation sequencing is an effective strategy to identify molecular variants within sickle cell disease patients.

Authors:  Marcia R Dezan; Ingrid Helena Ribeiro; Valéria B Oliveira; Juliana B Vieira; Francisco C Gomes; Lucas A M Franco; Leonardo Varuzza; Roberto Ribeiro; Karen Ziza Chinoca; José Eduardo Levi; José Eduardo Krieger; Alexandre Costa Pereira; Sandra F M Gualandro; Vanderson G Rocha; Alfredo Mendrone-Junior; Ester Cerdeira Sabino; Carla Luana Dinardo
Journal:  Blood Cells Mol Dis       Date:  2017-03-31       Impact factor: 3.039

6.  Blood transfusion and alloimmunization in patients with thalassemia: multicenter study.

Authors:  Azita Azarkeivan; Shahla Ansari; Mohammad Hossein Ahmadi; Bashir Hajibeigy; Mahtab Maghsudlu; Soheila Nasizadeh; Mojgan Shaigan; Abdolmajid Toolabi; Mitra Salahmand
Journal:  Pediatr Hematol Oncol       Date:  2011-09       Impact factor: 1.969

7.  Allele-specific oligonucleotide polymerase chain reaction for the determination of Rh C/c and Rh E/e antigens in thalassaemic patients.

Authors:  Mohammad Taher Hojjati; Nahid Einollahi; Fariba Nabatchian; Ali Akbar Pourfathollah; Mohammad Reza Mahdavi
Journal:  Blood Transfus       Date:  2011-01-13       Impact factor: 3.443

8.  Systematic RH genotyping and variant identification in French donors of African origin.

Authors:  Sandrine Kappler-Gratias; Carine Auxerre; Isabelle Dubeaux; Marylise Beolet; Maryline Ripaux; Pierre-Yves Le Pennec; Bach-Nga Pham
Journal:  Blood Transfus       Date:  2013-06-17       Impact factor: 3.443

9.  RHCE variants inherited with altered RHD alleles in Brazilian blood donors.

Authors:  C Prisco Arnoni; J Guilhem Muniz; T A de Paula Vendrame; R de Medeiros Person; F Roche Moreira Latini; L Castilho
Journal:  Transfus Med       Date:  2016-04-25       Impact factor: 2.019

10.  High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors.

Authors:  Stella T Chou; Tannoa Jackson; Sunitha Vege; Kim Smith-Whitley; David F Friedman; Connie M Westhoff
Journal:  Blood       Date:  2013-05-30       Impact factor: 22.113

View more
  1 in total

1.  Towards a Regional Registry of Extended Typed Blood Donors: Molecular Typing for Blood Group, Platelet and Granulocyte Antigens.

Authors:  Jan Portegys; Gabi Rink; Pia Bloos; Erwin A Scharberg; Harald Klüter; Peter Bugert
Journal:  Transfus Med Hemother       Date:  2018-09-24       Impact factor: 3.747

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.